Granted Patent B2

US 12,364,536 · App. 17/350,884 · Granted Jul 22, 2025

Inventors: Samuel J. Asirvatham (Rochester, MN); Mark B. Knudson (Shoreview, MN)

Assignee: Mayo Foundation for Medical Education and Research

A61B18/1492A61N1/0551A61N1/20A61B2018/00363A61B2018/00577A61B2018/00642A61B2018/0212A61B2018/1266A61B2018/1472A61N1/36057

Abstract

Claims (29)

1. A system for modulating an autonomic nervous system adjacent a pericardial space to treat cardiac arrhythmia of a heart, the system comprising:

a catheter defining a lumen between a proximal end and a distal end of the catheter, the distal end sized for insertion into the pericardial space;

a delivery assembly at least partially disposed within the lumen and including a proximal end and a distal end, the distal end being positionable in the pericardial space using the distal end of the catheter, the distal end of the delivery assembly comprising a delivery tip arranged to extend from the distal end of the catheter into the pericardial space;

a plurality of electrodes disposed on the delivery tip;

a source of non-thermal DC electrical energy configured to generate non-thermal DC electrical energy pulses that, when delivered via the plurality of electrodes within the pericardial space, treats the cardiac arrhythmia by inducing irreversible ablation of autonomic nervous structures of the heart while inducing only reversible effects to myocardial or pericardial tissue; and

an electrical connection operatively coupling the plurality of electrodes to the source of non-thermal DC electrical energy.

2. The system of claim 1 , further comprising a source of cooled fluid, and wherein the delivery tip defines one or more diffusion ports for infusing the cooled fluid into the pericardial space.

3. The system of claim 2 , wherein the cooled fluid is saline or another conductive solution.

4. The system of claim 2 , wherein the delivery tip defines a plurality of suction ports for evacuating fluid from the pericardial space.

5. The system of claim 1 , wherein the delivery tip further comprises a fluid retention element.

6. The system of claim 5 , wherein the fluid retention element comprises a fabric material, foam, or a sponge.

7. The system of claim 1 , wherein the source of non-thermal DC electrical energy is synchronizable with a QRS complex of the heart.

8. The system of claim 1 , further comprising an electrode disposed on the delivery tip and electrically coupled to a sensing circuit configured to detect activity of a ganglia on an epicardial surface.

9. The system of claim 1 , further comprising a monitoring and control system electrically coupled to the delivery tip and operable to control the source of non-thermal DC electrical energy.

10. The system of claim 9 , wherein the monitoring and control system is further operable to configure the source of non-thermal DC electrical energy to have a selected amplitude and a selected frequency.

11. A method of ablating or modulating ganglia of a heart to treat cardiac disorders, the method comprising:

advancing a distal end of a catheter into a pericardial space of the heart; and

delivering non-thermal DC electrical energy pulses from a plurality of electrodes located on a delivery tip extending from the distal end of the catheter,

wherein the non-thermal DC electrical energy pulses induce: (i) irreversible ablation of autonomic nervous structures of the heart and (ii) reversible effects to myocardial or pericardial tissue of the heart, and

wherein the non-thermal DC electrical energy pulses do not induce irreversible effects to the myocardial or pericardial tissue of the heart.

12. The method of claim 11 , further comprising, prior to delivering the non-thermal DC electrical energy pulses, infusing a conductive solution into the pericardial space via the delivery tip.

13. The method of claim 12 , wherein the conductive solution conducts the non-thermal DC electrical energy pulses to expand an area over which the non-thermal DC electrical energy pulses are effective.

14. The method of claim 12 , wherein the conductive solution comprises saline, a hypertonic saline solution, an alcohol solution, and/or ethanol.

15. The method of claim 12 , wherein the conductive solution is infused as a cooled fluid that provides a cryogenic effect to the myocardial or pericardial tissue of the heart.

16. The method of claim 12 , further comprising suctioning at least some of the conductive solution out of the pericardial space via the delivery tip.

17. The method of claim 11 , wherein the delivery tip comprises a fluid retention element.

18. The method of claim 17 , wherein the fluid retention element contains a beta blocker and/or is in flow communication with a source of the beta blocker.

19. The method of claim 17 , wherein the fluid retention element comprises a fabric material, foam, or a sponge.

20. The method of claim 11 , wherein the cardiac disorder treated by the method is neurocardiogenic syncope.

Assignments (1)

Continuity (6)

References Cited (76)